NBIX stock forecast
Our latest prediction for Neurocrine Biosciences, Inc.'s stock price was made on the Feb. 13, 2023 when the stock price was at 103.52$.
In the short term (2weeks), NBIX's stock price should underperform the market by -0.55%. During that period the price should oscillate between -4.53% and +3.90%.
In the medium term (3months), NBIX's stock price should outperform the market by 0.82%. During that period the price should oscillate between -19.66% and +14.15%.
Get email alertsCreate a solid portfolio with NBIX
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
At the moment the company generates 71M USD in revenues.
On its last earning announcement, the company reported a profit of 1.61$ per share.
The book value per share is 4.17$
Three months stock forecastFeb. 13, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71M | 2061.58% | 249M | 350.27% | 154M | 1.61 | - | - | 96M | 4.17 | - | - | - |